Skip to main content
Clinical Trials/ACTRN12606000486527
ACTRN12606000486527Completed未知

The effect of location of airflow measurement on the ability to assess Apnea Hypopnea Index (AHI) during Continuous Positive Airway Pressure (CPAP) therapy in patients with Obstructive Sleep Apnea (OSA) undergoing subtherapeutic CPAP and AutoCPAP therapy.

DiagnoseIT Pty Ltd, Sydney, NSW, Australia0 sites34 target enrollmentStarted: November 24, 2006Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
34

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to 70 Years (—)
Sex
All

Inclusion Criteria

  • Subjects must satisfy the following inclusion criteria:Previously diagnosed with moderate-severe obstructive sleep apnea (RDI>15)Compliant CPAP use for at least 3 months durationCompliance: CPAP use > 4 hours per night for at least 5 nights per week No significant problems with CPAP therapy such as mask/mouth leak or severe nasal congestion. English speaking.

Exclusion Criteria

  • Other sleep disorders including:PLMD Untreated RLS >10 Central apnoeas/hr on diagnostic sleep studyNeurological disordersPsychiatric disordersSignificant medical complaint including:Severe cardiovascular disease Congestive heart failure Significant lung disease (e.g., chronic obstructive pulmonary disease) Daytime hypoxemia and respiratory failure from any cause Prominent nocturnal desaturation other than from OSA (e.g., obesity hypoventilation syndrome).

Investigators

Sponsor
DiagnoseIT Pty Ltd, Sydney, NSW, Australia

Similar Trials